MA32838B1 - Procede de modulation de l'activite antagoniste d'un anticorps monoclonal - Google Patents

Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Info

Publication number
MA32838B1
MA32838B1 MA33899A MA33899A MA32838B1 MA 32838 B1 MA32838 B1 MA 32838B1 MA 33899 A MA33899 A MA 33899A MA 33899 A MA33899 A MA 33899A MA 32838 B1 MA32838 B1 MA 32838B1
Authority
MA
Morocco
Prior art keywords
antibody
antibody activity
modifying
monoclonal antibodies
target molecule
Prior art date
Application number
MA33899A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/055664 external-priority patent/WO2010064090A1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32838B1 publication Critical patent/MA32838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention a trait au domaine de l'ingénierie des anticorps et plus particulièrement à un procédé de criblage d'anticorps et/ou de modulation de l'activité agoniste ou antagoniste d'anticorps, et plus particulièrement encore à un procédé améliorant l'activité antagoniste d'un anticorps monoclonal dirigé contre une molécule cible spécifique ou contre l'un de ses fragments fonctionnels divalents ou l'un de ses dérivés, ledit anticorps étant capable d'inhiber une ou plusieurs des activités biologiques de ladite molécule cible, et ledit procédé comportant une étape de reconfiguration de la région charnière, consistant à modifier la séquence d'acides aminés de ladite région par suppression, addition ou substitution d'au moins un acide aminé. L'invention porte également sur des polypeptides utilisables dans ladite méthode de modulation, et sur les anticorps ainsi obtenus.
MA33899A 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal MA32838B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (fr) 2008-12-02 2008-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal
US18440609P 2009-06-05 2009-06-05
PCT/EP2009/066205 WO2010063746A1 (fr) 2008-12-02 2009-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal

Publications (1)

Publication Number Publication Date
MA32838B1 true MA32838B1 (fr) 2011-11-01

Family

ID=41668304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33899A MA32838B1 (fr) 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Country Status (21)

Country Link
US (3) US9676839B2 (fr)
EP (2) EP3048113A1 (fr)
JP (1) JP5832899B2 (fr)
KR (2) KR20110091519A (fr)
CN (2) CN102232086B (fr)
AR (1) AR074438A1 (fr)
AU (1) AU2009324145B2 (fr)
BR (1) BRPI0923228B1 (fr)
CA (1) CA2744065C (fr)
DK (1) DK2370464T3 (fr)
ES (1) ES2600254T3 (fr)
GE (1) GEP20135931B (fr)
IL (1) IL213272A (fr)
MA (1) MA32838B1 (fr)
MX (1) MX2011005569A (fr)
NZ (1) NZ592830A (fr)
SA (1) SA109300723B1 (fr)
TN (1) TN2011000253A1 (fr)
TW (1) TWI631341B (fr)
WO (1) WO2010063746A1 (fr)
ZA (1) ZA201103831B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
IN2014DN10515A (fr) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
WO2007114325A1 (fr) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
EP2409991B1 (fr) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variant d'une région constante d'anticorps
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
ES2993335T3 (en) 2010-03-10 2024-12-27 Genmab As Monoclonal antibodies against c-met
EP2708556B1 (fr) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Composition pharmaceutique à utiliser dans une thérapie combinée pour la prévention ou le traitement des maladies induites par c-met ou le facteur d'angiogénèse
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3122779B1 (fr) * 2014-03-24 2019-05-22 Cancer Research Technology Limited Anticorps modifiés contenant des domaines d'igg2 modifiés conférant des propriétés agonistes ou antagonistes, et utilisation de ces derniers
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TWI784917B (zh) 2015-09-23 2022-11-21 美商再生元醫藥公司 最優化抗ｃｄ３雙特異性抗體及其用途
CA3004288C (fr) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Méthode de promotion de l’efficacité d’épuration d’un polypeptide contenant la région fc
EP3532497B1 (fr) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Régions charnières d'immunoglobuline modifiées pour réduire l'hémagglutination
EP3807317A4 (fr) * 2018-06-15 2022-03-30 The Regents of University of California Récepteurs antigéniques chimériques de fragments de fusion et utilisations associées
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
WO2022104692A1 (fr) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anticorps modifié, conjugué anticorps-médicament et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2397631T3 (es) * 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
WO2006116260A2 (fr) * 2005-04-26 2006-11-02 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
SG196835A1 (en) * 2005-07-18 2014-02-13 Amgen Inc Human anti-b7rp1 neutralizing antibodies
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
AU2007227963A1 (en) * 2006-03-23 2007-09-27 Kyowa Hakko Kirin Co., Ltd. Agonist antibody to human thrombopoietin receptor
CN101415730B (zh) 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
KR20170021378A (ko) 2017-02-27
NZ592830A (en) 2013-03-28
GEP20135931B (en) 2013-10-10
RU2011124749A (ru) 2013-01-10
ZA201103831B (en) 2012-01-25
ES2600254T3 (es) 2017-02-08
TN2011000253A1 (en) 2012-12-17
BRPI0923228B1 (pt) 2022-03-03
SA109300723B1 (ar) 2014-10-27
IL213272A0 (en) 2011-07-31
CN102232086B (zh) 2016-03-16
TWI631341B (zh) 2018-08-01
CA2744065C (fr) 2017-09-12
US20150239958A1 (en) 2015-08-27
JP2012510281A (ja) 2012-05-10
WO2010063746A1 (fr) 2010-06-10
KR20110091519A (ko) 2011-08-11
BRPI0923228A2 (pt) 2021-02-09
US20110263830A1 (en) 2011-10-27
EP2370464A1 (fr) 2011-10-05
AU2009324145A1 (en) 2010-06-10
AU2009324145B2 (en) 2015-01-22
IL213272A (en) 2017-08-31
CN105820241A (zh) 2016-08-03
EP3048113A1 (fr) 2016-07-27
HK1163704A1 (zh) 2012-09-14
CA2744065A1 (fr) 2010-06-10
CN102232086A (zh) 2011-11-02
MX2011005569A (es) 2011-06-16
US9676839B2 (en) 2017-06-13
KR101971806B1 (ko) 2019-08-27
EP2370464B1 (fr) 2016-07-27
JP5832899B2 (ja) 2015-12-16
TW201024734A (en) 2010-07-01
AR074438A1 (es) 2011-01-19
US20130109839A1 (en) 2013-05-02
DK2370464T3 (en) 2016-11-21

Similar Documents

Publication Publication Date Title
MA32838B1 (fr) Procede de modulation de l'activite antagoniste d'un anticorps monoclonal
WO2010091182A3 (fr) Procédés pour cribler des agents candidats pour la modulation de la prorénine et de la rénine, tests de détection de la prorénine, et anticorps qu'ils emploient
MY157173A (en) Modified humanised anti-interleukin-18
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
EA201001762A1 (ru) Антитела и способы их получения
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
DE602006013029D1 (de) Anti-egfr-antikörper
MX358705B (es) Agentes de union de esclerostina.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201592042A1 (ru) Композиции антител против cgrp и их применение
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
ECSP14013220A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
ATE549358T1 (de) Neuer anti-plgf-antikörper
MX2013002323A (es) Anticuerpos para metaloproteinasa.
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
EA201790757A1 (ru) Связывающие антиген cd27l белки
GB201005064D0 (en) Biological products
NZ594682A (en) Fully human antibodies specific to cadm1
EA201201526A1 (ru) Способы лечения состояний, связанных с il-1b
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper